NCT05604209View on ClinicalTrials.gov

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

September 12, 2024

Study Completion Date

January 10, 2025

Conditions
HIV VaccineHIV-1-infection
Interventions
BIOLOGICAL

ChAdOx1.HIVconsv62

Administered intramuscularly (IM) at Day 0

BIOLOGICAL

ChAdOx1.tHIVconsv1

Administered intramuscularly (IM) at Day 0

BIOLOGICAL

MVA.tHIVconsv4

Administered intramuscularly (IM) at Day 28

BIOLOGICAL

MVA.tHIVconsv3

Administered intramuscularly (IM) at Day 28

OTHER

Placebo

Administered at intramuscularly (IM) Day 0 and Day 28

Trial Locations (2)

27514

University of North Carolina, Chapel Hill

27703

Duke University, Durham

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of North Carolina, Chapel Hill

OTHER